scholarly journals Long-term glycemic control and the rate of progression of early diabetic kidney disease

1993 ◽  
Vol 44 (4) ◽  
pp. 855-859 ◽  
Author(s):  
Richard E. Gilbert ◽  
Con Tsalamandris ◽  
Leon A. Bach ◽  
Sianna Panagiotopoulos ◽  
Richard C. O'Brien ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Glycemic Control ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Rate Of Progression

Abstract 016: Profound and Sustained Amplification of Circulating ACE2 Activity Does Not Protect Diabetic Mice from Kidney Disease

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Jan Wysocki ◽  
Minghao Ye ◽  
Ahmed M Khattab ◽  
Yashpal Kanwar ◽  
Mark Osborn ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Kidney Injury ◽  
Renin Angiotensin System ◽  
Diabetic Mice ◽  
Diabetic Kidney ◽  
Over Expression ◽  
Akita Mice

ACE2 is a monocarboxypeptidase that by converting AngII to Ang1-7 should down-regulate the renin-angiotensin system and therefore provide a means to therapeutically target diabetic kidney disease, a condition where the kidney RAS is overactive. Previous work indicated that soluble human recombinant (r)ACE2 administration for 4 weeks attenuated kidney injury in diabetic Akita mice. Whether such effect of rACE2 can be confirmed and attributed to augmented ACE2 activity is uncertain because chronic use of human rACE2 in mice induces immunogenicity and the development of antibodies that neutralize serum ACE2 activity. To examine the effect of chronic amplification of circulating ACE2 on kidney injury caused by STZ-induced diabetes and to circumvent the immunogenicity arising from xenogeneic ACE2, ACE2 of mouse origin was administered to mice using either daily i.p. injections (1 mg/kg) of mrACE2 for 4 weeks or after 20 weeks of ACE2 mini-circle (MC) (10-30ug/mouse) administration. MC provides a form of gene delivery that is resistant to gene silencing and, in addition, greatly optimizes long-term in vivo overexpression of proteins of interest. ACE2MC resulted in a profound and sustained increase in serum ACE2 activity (2.4±0.3 vs. 497±135 RFU/ul/hr, p<0.01) but kidney ACE2 activity was unchanged (17.4±1.3 vs. 19.0±0.8 RFU/ug prot/hr). mACE2-treated mice injected with STZ developed diabetes similar to sham mice injected with STZ. Systolic BP was not different between non-diabetic mice, sham STZ-mice, and STZ-mice receiving mACE2 by either i.p. mrACE2 or ACE2MC. Urinary albumin was similarly increased in sham STZ-mice and in STZ-mice receiving mACE2. Glomerular mesangial score and glomerular cellularity were both increased to a similar extent in sham STZ-mice and in STZ-mice with mACE2 administration, as compared to non-diabetic controls. In conclusion, profound and long-term augmentation of ACE2 activity confined to the circulation is not sufficient to attenuate glomerular pathology and albuminuria in STZ-induced diabetic kidney disease probably because of lack of kidney delivery of ACE2. Strategies to achieve over-expression of ACE2 at the kidney level are needed to demonstrate a beneficial effect of this enzyme on diabetic kidney disease.

scholarly journals SUN-311 NF-KAPPA B ACTIVATION PROMOTES GLOMERULAR INJURY AND INFLAMMATION IN LONG-TERM EXPERIMENTAL DIABETIC KIDNEY DISEASE

2019 ◽  
Vol 4 (7) ◽  
pp. S289
Author(s):  
O. FORESTO-NETO ◽  
A.H. Albino ◽  
S.C.A. Arias ◽  
V.D. Faustino ◽  
F.F.F. Zambom ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Glomerular Injury ◽  
Nf Kappa B ◽  
Diabetic Kidney

Glycemic Control as Primary Prevention for Diabetic Kidney Disease

2018 ◽  
Vol 25 (2) ◽  
pp. 141-148 ◽  
Author(s):  
Richard J. MacIsaac ◽  
George Jerums ◽  
Elif I. Ekinci
Keyword(s):  
Primary Prevention ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney

Mo2042 The Effect of Roux-en-Y Gastric Bypass on Glycemic Control and Diabetic Kidney Disease in the Zucker Diabetic Fatty Rat Model

2014 ◽  
Vol 146 (5) ◽  
pp. S-725
Author(s):  
Jessie A. Elliott ◽  
Karl J. Neff ◽  
Thomas A. Lutz ◽  
Caroline Corteville ◽  
Neil Docherty ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Rat Model ◽  
Diabetic Kidney Disease ◽  
Zucker Diabetic Fatty Rat ◽  
Diabetic Kidney

scholarly journals A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study

2020 ◽  
Vol 9 (7) ◽  
pp. 2160
Author(s):  
Nancy Helou ◽  
Dominique Talhouedec ◽  
Maya Zumstein-Shaha ◽  
Anne Zanchi
Keyword(s):  
Quality Of Life ◽  
Renal Function ◽  
Kidney Disease ◽  
Glycemic Control ◽  
Usual Care ◽  
Diabetic Kidney Disease ◽  
Self Management ◽  
Diabetic Kidney ◽  
Diet Habits

Individuals with diabetic kidney disease are at high risk of complications and challenged to self-manage. Previous research suggested that multidisciplinary approaches would improve health outcomes. This study investigated the effect of a multidisciplinary self-management approach of diabetic kidney disease on quality of life, and self-management, glycemic control, and renal function. A uniform balanced crossover design was used because it attains a high level of statistical power with a lower sample size. A total of 32 participants (aged 67.8 ± 10.8) were randomized into four study arms. In differing sequences, each participant was treated twice with three months of usual care alternated with three months of multidisciplinary management. The intervention improved the present dimension of quality of life demonstrating higher mean rank as compared to usual care (52.49 vs. 41.01; p = 0.026, 95% CI) and three self-care activities, general diet habits, diabetes diet habits, and blood sugar testing (respectively: 55.43 vs. 38.31; p = 0.002, 56.84 vs. 37.02; p = 0.000, 53.84 vs. 39.77; p = 0.008; 95% CI). Antihypertensive medication engagement was high across the study period (Mean = 95.38%, Min = 69%, Max = 100%). Glycemic control and renal function indicators were similar for the intervention and the usual care. Studies are needed to determine how the new recommended therapies for diabetic kidney disease such as SGLT2 inhibitors and GLP-1 receptor agonists impact on self-management and quality of life.

Sign in / Sign up

Export Citation Format

Share Document